Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 4/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.30 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.30 |
| ▸ | ICMT | O60725 | 1/20 | 0.30 |
| ▸ | CTSA | P10619 | 2/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341005 | 0.90 | CSNK1E (0.34) | CSNK1ECSNK1DEGFRADORA1DCAF1 | |
| SCHEMBL4335958 | 0.88 | PIK3CD (0.34) | KDM4EALDH1A1LMNAEGFRCTSA | |
| SCHEMBL4342241 | 0.82 | CSNK1E (0.34) | CSNK1ECSNK1DKDM4EDCAF1HCRTR1 | |
| SCHEMBL4348191 | 0.81 | KDM4E (0.35) | KDM4EALDH1A1HTT | |
| SCHEMBL4332589 | 0.81 | ACLY (0.33) | — | |
| SCHEMBL6426342 | 0.80 | ENPP2 (0.31) | — | |
| SCHEMBL4343214 | 0.75 | CSNK1E (0.35) | CSNK1ECSNK1DKDM4EALDH1A1LMNA | |
| SCHEMBL4339201 | 0.67 | JAK2 (0.38) | CSNK1ECSNK1DKDM4EEGFRHCRTR1 | |
| SCHEMBL4333973 | 0.67 | PLAU (0.33) | — | |
| SCHEMBL4340947 | 0.66 | PTGER1 (0.36) | CSNK1ECSNK1DDCLRE1BICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | CSNK1E 202/4885CSNK1D 134/4885KDM4E 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.